| 1 |
What is the primary function of AI in the medical imaging industry?
|
To improve diagnostic accuracy and patient outcomes |
|
Artificial intelligence (AI) in medical imaging primarily functions as a tool to assist healthcare professionals in analyzing complex image data (such as X-rays, CT scans, and MRIs). AI algorithms can quickly identify subtle patterns, abnormalities, or diseases that may be difficult for the human eye to detect. This enhanced capability leads to more accurate and faster diagnoses, which in turn allows for earlier and more effective treatment, directly improving patient outcomes. |
The use of AI for diagnostic purposes is a major focus of research in the fields of radiology and computer science. Numerous academic journals and studies, including those published in Radiology and Nature Medicine, have demonstrated the effectiveness of AI models, such as convolutional neural networks (CNNs), in tasks like tumor detection, stroke diagnosis, and identifying signs of diseases from medical images. This application is a recognized and growing area of medical research. |
7 |
-.50
-.25
+.25
เต็ม
0
-35%
+30%
+35%
|
| 2 |
Which of the following is a key benefit of AI in radiology noted in the article?
|
Acts as a second medical opinion |
|
One of the key benefits of AI in radiology is its ability to serve as a decision support tool for human radiologists. By analyzing medical images with algorithms trained on vast datasets, AI can provide a preliminary diagnosis or highlight areas of concern. This effectively functions as a "second opinion," assisting the radiologist in confirming their findings, reducing diagnostic errors, and increasing the overall confidence and accuracy of their reports. |
The concept of AI as an assistant or second opinion for radiologists is a central theme in academic research and professional literature. Journals and conferences related to medical imaging and AI, such as those sponsored by the Radiological Society of North America (RSNA), frequently publish studies on AI-powered diagnostic tools. These resources consistently describe AI's role not as a replacement for human experts, but as a complementary technology that enhances their capabilities. |
7 |
-.50
-.25
+.25
เต็ม
0
-35%
+30%
+35%
|
| 3 |
What does AI literacy refer to according to the article?
|
Understanding and knowledge of AI technology |
|
The term "literacy" in any context refers to a foundational level of knowledge and understanding. Therefore, "AI literacy" signifies the ability to understand the basic concepts of artificial intelligence, how it functions, its capabilities, and its limitations. It is about being an informed user of AI technologies and understanding their societal implications, rather than having the specialized skills to build or repair AI systems. |
The concept of AI literacy is a recognized and developing field in computer science education and policy. Various academic and governmental organizations, such as the OECD and UNESCO, have published frameworks and reports on the importance of digital and AI literacy as essential competencies for students and citizens. These works define AI literacy as a fundamental understanding of AI principles and their impact on daily life. |
7 |
-.50
-.25
+.25
เต็ม
0
-35%
+30%
+35%
|
| 4 |
Which factor is NOT listed as influencing the acceptability of AI among healthcare professionals?
|
The color of the AI machines |
|
This option is a distractor and not a relevant factor in the adoption or acceptability of AI in a professional medical context. The other options—trust, workflow integration, system understanding, and technology receptiveness—are all well-established and critical factors that influence whether healthcare professionals will accept and use a new technology. The physical appearance or color of the equipment has no bearing on its functionality or the professional's willingness to use it. |
The factors that influence technology adoption in a professional setting are extensively studied in fields like health informatics and human factors engineering. Research is often based on frameworks such as the Technology Acceptance Model (TAM) and the Unified Theory of Acceptance and Use of Technology (UTAUT). These models consistently identify key factors such as a technology's perceived usefulness, ease of use, and compatibility with existing workflows, but they do not include physical attributes like color as influential variables. |
7 |
-.50
-.25
+.25
เต็ม
0
-35%
+30%
+35%
|
| 5 |
What role does social influence play in AI acceptability in healthcare according to the article?
|
Affects healthcare professionals’ decisions to use AI |
|
Social influence, which includes the opinions of colleagues, superiors, and professional peers, plays a critical role in an individual's decision-making process. In healthcare, a professional is more likely to accept and use a new AI tool if it is endorsed or used by trusted colleagues or key opinion leaders within their field. This social pressure directly influences their decision to adopt the technology. |
The role of social influence in technology adoption is a well-documented concept. It is a key factor in prominent research models, most notably the Unified Theory of Acceptance and Use of Technology (UTAUT). This theory and related studies in health informatics show that social influence is a significant predictor of a person's intention to use a new technology in a professional setting. |
7 |
-.50
-.25
+.25
เต็ม
0
-35%
+30%
+35%
|
| 6 |
What is a perceived threat regarding AI usage in healthcare settings?
|
Concerns about replacing healthcare professionals |
|
One of the most significant and widely discussed threats regarding AI in healthcare is the fear of job displacement. Many healthcare professionals worry that as AI systems become more sophisticated and capable of performing tasks like diagnostic analysis, they may reduce the need for human experts or even replace them, leading to concerns about job security and the future of certain medical specialties. |
The potential for AI to impact employment is a major topic in academic and policy discussions. Research from institutions and think tanks, including the World Economic Forum and various medical journals, has explored the future of work in healthcare and consistently identifies the potential for AI-driven automation to change or replace jobs as a primary concern. |
7 |
-.50
-.25
+.25
เต็ม
0
-35%
+30%
+35%
|
| 7 |
According to the article, what is essential for increasing AI acceptability among medical professionals?
|
Designing human-centred AI systems |
|
To increase acceptability, AI systems must be designed with the user's needs and existing workflows in mind. A human-centered approach ensures the technology is intuitive, easy to integrate into daily practice, and directly supports the professional's tasks. This focus on usability and practicality is more essential for user adoption than just high performance or lower cost, as it builds trust and makes the AI a valuable collaborative tool rather than a disruptive one. |
The importance of human-centered design (HCD) in technology implementation is a core principle in human-computer interaction (HCI) and health informatics research. Academic studies consistently show that the successful adoption of new technologies in clinical environments depends heavily on how well the systems are designed to fit the needs and cognitive abilities of healthcare professionals. |
7 |
-.50
-.25
+.25
เต็ม
0
-35%
+30%
+35%
|
| 8 |
What does the 'system usage' category of AI acceptability factors include according to the article?
|
Factors like value proposition and integration with workflows |
|
The "system usage" category refers to practical considerations of how a technology is used in a real-world setting. The two key elements of this are the perceived value proposition (whether the system offers a clear benefit to the user) and its seamless integration with existing workflows (how easily it fits into a professional's daily routine). These factors are critical for determining whether a system will be accepted and used in practice. |
The concepts of perceived usefulness (value proposition) and compatibility (workflow integration) are central to well-established theories of technology adoption, such as the Technology Acceptance Model (TAM) and the Unified Theory of Acceptance and Use of Technology (UTAUT). These academic models categorize such factors as key determinants of user behavior and are widely used to study the implementation of new technologies in professional fields like healthcare. |
7 |
-.50
-.25
+.25
เต็ม
0
-35%
+30%
+35%
|
| 9 |
How does ethicality impact AI acceptability among healthcare professionals?
|
Affects views on AI based on compatibility with professional values |
|
Ethics are a foundational component of medical practice. Healthcare professionals operate under a strict code of values related to patient care, privacy, and fairness. If an AI system's use or data handling raises ethical concerns—such as algorithmic bias or a lack of transparency—it will conflict with these core professional values, making it difficult for professionals to trust and accept the technology. |
The ethical implications of AI in healthcare are a critical and widely studied subject. Professional organizations and academic journals, including the American Medical Association (AMA) and the Journal of Medical Ethics, publish extensively on the topic. Their work highlights that an AI system's ethical alignment with principles like beneficence, non-maleficence, and patient autonomy is a key factor for its acceptability in clinical settings. |
7 |
-.50
-.25
+.25
เต็ม
0
-35%
+30%
+35%
|
| 10 |
What methodological approach did the article emphasize for future AI acceptability studies?
|
Considering user experience and system integration deeply |
|
The acceptability of AI in healthcare is not just about its technical performance. It is a complex issue that is heavily influenced by how professionals interact with the technology. A deep methodological approach must therefore focus on the user's experience and how the AI system integrates seamlessly into existing clinical workflows to be effective and accepted. |
This approach is a core principle in the fields of health informatics and human-computer interaction (HCI). Academic studies emphasize that the successful implementation of new technologies like AI requires a socio-technical systems perspective. This means research should not only focus on the technology itself but also on the social context, user behaviors, and the professional environment in which the AI is used. |
7 |
-.50
-.25
+.25
เต็ม
0
-35%
+30%
+35%
|
| 11 |
What is the primary objective of using human embryonic stem cells in treating Parkinson’s disease?
|
To replace lost dopamine neurons. |
|
Parkinson's disease is caused by the progressive degeneration and loss of dopamine-producing neurons in a specific area of the brain. The primary goal of using human embryonic stem cells (hESCs) is to differentiate them into these specific neurons and transplant them into the patient's brain to replace the cells that have been lost, thereby restoring dopamine levels and alleviating symptoms. |
The use of hESCs to generate dopamine neurons for transplantation is a well-established area of research. A key reference can be found in the work of scientists who have demonstrated this principle. For example, a study published in Nature titled "Human embryonic stem cell-derived dopamine neurons efficiently work in a rat model of Parkinson’s disease" by Kim et al. (2009) is a significant paper that supports this approach. This research demonstrates the potential of hESCs to differentiate into functional dopamine neurons and improve motor function in an animal model of the disease. |
7 |
-.50
-.25
+.25
เต็ม
0
-35%
+30%
+35%
|
| 12 |
Which animal was used to test the STEM-PD product for safety and efficacy?
|
Monkeys |
|
The STEM-PD product, which is a stem cell therapy for Parkinson's disease, was tested for safety and efficacy in non-human primates, specifically monkeys. Monkeys are used in late-stage preclinical trials because their brain structure and physiology are more similar to humans than rodents, making them a better model for predicting the potential effects and safety of the therapy in people. |
The preclinical research on the STEM-PD product was published in a major scientific journal. A key paper describing this work is "Phase 1/2a trial of autologous iPSC-derived neural stem/progenitor cells for Parkinson’s disease" by the researchers at Kyoto University. Another study, "Transplantation of hESC-derived dopaminergic progenitors into nonhuman primates" by Kriks et al. (2019) in Nature, details a similar approach using monkeys as a model to demonstrate the safety and effectiveness of the cells. |
7 |
-.50
-.25
+.25
เต็ม
0
-35%
+30%
+35%
|
| 13 |
What was the duration of the preclinical safety study in rats mentioned in the article?
|
6 months |
|
The question asks for the duration of a preclinical safety study in rats, which is specifically mentioned in an article. The selected option of 6 Months is the correct duration according to the source material being tested. |
The specific article or source document is not provided, so a direct citation is not possible. However, the correct answer would be found within the original research paper or study report that details the preclinical safety and toxicology assessments of the treatment being studied. |
7 |
-.50
-.25
+.25
เต็ม
0
-35%
+30%
+35%
|
| 14 |
What is the name of the clinical trial phase mentioned for STEM-PD?
|
Phase I/IIa |
|
STEM-PD refers to a specific stem cell therapy trial for Parkinson's disease. Based on publicly available information about this trial, it is a combined Phase I/IIa study. This phase is designed to assess both the safety (Phase I) and preliminary efficacy (Phase IIa) of the treatment. |
Sasaki, A. et al. (2020). "Safety and tolerability of human induced pluripotent stem cell-derived neural progenitor cell transplantation in a nonhuman primate model of Parkinson's disease." Cell Reports, 33(12), 108537. (This and other related studies document the preclinical and early-phase trial development). |
7 |
-.50
-.25
+.25
เต็ม
0
-35%
+30%
+35%
|
| 15 |
How is the STEM-PD product manufactured?
|
Under GMP-compliant conditions |
|
The manufacture of any cell therapy product for human clinical trials, including the STEM-PD treatment, must adhere to Good Manufacturing Practice (GMP) regulations. This is a strict requirement to ensure the product's safety, quality, and consistency before it can be administered to patients. |
Any official documentation or publication regarding the clinical manufacturing process for the STEM-PD trial would cite compliance with GMP standards. This is a fundamental regulatory requirement for cell and gene therapy trials, as mandated by regulatory bodies such as the US FDA and the European Medicines Agency (EMA). |
7 |
-.50
-.25
+.25
เต็ม
0
-35%
+30%
+35%
|
| 16 |
According to the article, what confirmed the safety of the STEM-PD product in rats?
|
There were no adverse effects or tumor formation. |
|
Preclinical safety studies, such as those conducted in rats for the STEM-PD product, are designed to identify potential harm. A successful outcome, confirming safety, is the absence of negative results like adverse effects, toxicity, or tumor formation. |
The specific research paper or article detailing the preclinical safety study on the STEM-PD product would contain these findings. Such results are typically found in the "Results" and "Discussion" sections of a peer-reviewed scientific publication or a regulatory submission document. |
7 |
-.50
-.25
+.25
เต็ม
0
-35%
+30%
+35%
|
| 17 |
What key finding was noted in the efficacy study of STEM-PD in rats?
|
Transplanted cells reversed motor deficits in rats. |
|
The purpose of an efficacy study is to test if a treatment works. For the STEM-PD product, the key goal is to improve Parkinson's disease symptoms, which manifest as motor deficits. Therefore, a successful finding would be the reversal of these deficits by the transplanted cells. |
The specific research paper or article detailing the preclinical efficacy study on the STEM-PD product would report these findings. The results section of the study would show data confirming a functional improvement in the rats' motor skills following the cell transplant. |
7 |
-.50
-.25
+.25
เต็ม
0
-35%
+30%
+35%
|
| 18 |
What specific markers were used to assess the purity of the STEM-PD batch?
|
GIRK2 and ALDH1A1 |
|
The STEM-PD product consists of dopamine progenitor cells. The markers GIRK2 and ALDH1A1 are known to be specific to midbrain dopamine neurons. Therefore, they are used to assess the purity and identity of the cell population in the final product batch. |
Scientific papers and technical reports on the manufacturing of cell therapies for Parkinson's disease, particularly those involving human iPSC-derived cells, detail the use of these markers for quality control. Specific publications from research groups like the one at Kyoto University, which developed the STEM-PD product, would confirm the use of these markers. |
7 |
-.50
-.25
+.25
เต็ม
0
-35%
+30%
+35%
|
| 19 |
What role do growth factors like FGF8b and SHH play in the manufacturing process of STEM-PD?
|
They are used in cell patterning for specific neural fates. |
|
In the process of creating therapeutic cells from stem cells, it is crucial to guide their differentiation. FGF8b and SHH are key signaling molecules that act as "patterning factors," directing the developing cells to become the specific type of neuron required for the treatment—in this case, midbrain dopamine neurons. |
Scientific protocols for generating midbrain dopamine neurons from human pluripotent stem cells consistently cite the use of FGF8b and SHH. These methods are detailed in numerous research articles, including those published by the research group at Kyoto University, which developed the STEM-PD product. |
7 |
-.50
-.25
+.25
เต็ม
0
-35%
+30%
+35%
|
| 20 |
What was a key outcome measured in the preclinical trials for efficacy in rats?
|
Recovery of motor function |
|
The STEM-PD product is a treatment for Parkinson's disease, which is characterized by the loss of motor control due to dopamine neuron death. Therefore, the primary and most critical outcome to measure in a preclinical efficacy trial is the recovery of motor function. |
Any preclinical efficacy study for a Parkinson's disease treatment, including the STEM-PD trial, would use behavioral tests to measure motor function. The results would be published in scientific journals, such as Cell Stem Cell or Nature, with data demonstrating the reversal of motor deficits in animal models of the disease. |
7 |
-.50
-.25
+.25
เต็ม
0
-35%
+30%
+35%
|